Dealmaking: Q3 Roundup Shows Deal Values Jump From Prior Quarter

A look at M&A and alliance activity across the medical device and in vitro diagnostics industries, July-September 2020

Device company M&A values reached $17.9bn in Q3, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $8.2bn.

M and A diagram, Businessman hand touching M&A (Merger and Acquisition) sign on virtual screen

Featuring 24 completed device M&A transactions, half of which had disclosed values together totaling $17.9bn, the third quarter showed an exponential increase in deal value (and deal volume also notably rose) from Q2’s $159m (for five completed deals; see Exhibit 1). At the top, making up 92% of the Q3 total was Siemens Healthineers AG’s definitive agreement to acquire public radiotherapy developer Varian Medical Systems, Inc.. in an all-cash transaction valued at $16.4bn. ([A#MT142548])

Even without this transaction, the Q3 deal value, at $1.5bn, was still almost 10 times more than the previous quarter.

More from Deals

More from Business

Aneira Health Launches New Precision Medicine Platform Exclusively For Women

 

Cecilia Lindgren, Aneira Health’s co-founder and chief science officer, said that the company has “redesigned the diagnostic model.” The subscription-based platform offers clinical-grade and AI diagnostics alongside clinical consultation.

Thermo Fisher Cuts Annual Profit Outlook Amid Estimated $400M Tariff Hit

 
• By 

Thermo Fisher is aggressively managing its supply chain and cost base using its Practical Process Improvement (PPI) Business System. The company is also increasing investments in US-based manufacturing and R&D, with around $2bn allocated to bolster domestic operations.

‘Small Business’ Applications For Waiver Of Device User Fees To Be Streamlined By US FDA

 

FDA moves forward with implementing previous draft guidance and will consolidate forms, but the agency estimates limited impact in the total reporting burden.